Skip to main content
. 2016 Sep 1;11(9):e0162147. doi: 10.1371/journal.pone.0162147

Fig 3. LC–MS/MS analysis for 14, 15–EET, 14, 15–DHET, and 11,12–DHET levels in WT and t-AUCB-treated WT mouse heart perfusates at baseline (pre-ischemia) and directly after 15-second ischemia (post-ischemia).

Fig 3

(A) At baseline and post-ischemia levels of 14, 15–EET had an increasing trend in t-AUCB-treated WT versus WT mice, but this trend was not significant. (B) 14, 15–DHET levels decreased at baseline and post-ischemia in t-AUCB-treated WT versus WT (p < 0.0001). (C) The 14, 15–EET/14, 15–DHET ratio increased (p < 0.05) in t-AUCB-treated WT versus WT mice at baseline (by 96%) and post-ischemia (by 173%). (D) 11, 12–DHET levels decreased (p < 0.001) at baseline and post-ischemia in t-AUCB-treated-WT versus WT mice. There was no difference in 14,15-EET, 14,15-DHET, and 11,12-DHET levels pre- and post-ischemia within each group. * p < 0.05 versus baseline WT. # p < 0.05 versus post-ischemia WT. n = 8.